CAVA Group Inc vs Revvity Inc — how do they compare? CAVA Group Inc trades at $67.8 (market cap $7.08B), while Revvity Inc trades at $116 (market cap $12.91B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.24% dividend while CAVA Group Inc pays none. Which is the better fit depends on your goals.
| CAVA | RVTY | |
|---|---|---|
Market Cap | $7.08B | $12.91B |
Sector | Consumer Cyclical | Technology |
52-Week High | $97.39 | $117.75 |
52-Week Low | $43.59 | $82.26 |
Enterprise Value | $7.23B | $15.23B |
Dividend Yield | — | 0.24% |
Signals from Pluang's Aura AI — not financial advice
CAVA trades at $69.68, up 13.15% with strong Q2 2026 earnings beats and 31.3% revenue growth. Technicals are bearish with support at $58, while fundamentals show high P/E of 108.59 but robust same-store sales. News highlights include menu innovation driving traffic and earnings outperformance.
Outlook is positive with a $89.75 consensus price target and 76% buy ratings, though valuation and net cash outflows pose risks. Growth momentum from new restaurants and consumer demand supports upside, but margin pressure and competition require monitoring.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →